CNTX vs. GRFS, LVTX, MYNZ, NLSP, PHVS, TLSA, ATNFW, SXTPW, ACONW, and AIMDW
Should you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.
Grifols (NASDAQ:GRFS) and Context Therapeutics (NASDAQ:CNTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
Grifols has higher revenue and earnings than Context Therapeutics.
Grifols received 336 more outperform votes than Context Therapeutics when rated by MarketBeat users. However, 63.16% of users gave Context Therapeutics an outperform vote while only 55.95% of users gave Grifols an outperform vote.
14.0% of Context Therapeutics shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 9.4% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Grifols has a net margin of 0.90% compared to Grifols' net margin of 0.00%. Context Therapeutics' return on equity of 1.73% beat Grifols' return on equity.
In the previous week, Context Therapeutics had 5 more articles in the media than Grifols. MarketBeat recorded 11 mentions for Context Therapeutics and 6 mentions for Grifols. Grifols' average media sentiment score of 0.96 beat Context Therapeutics' score of 0.37 indicating that Context Therapeutics is being referred to more favorably in the news media.
Grifols presently has a consensus price target of $10.50, indicating a potential upside of 40.56%. Context Therapeutics has a consensus price target of $7.50, indicating a potential upside of 338.60%. Given Grifols' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Grifols.
Grifols has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.
Summary
Context Therapeutics beats Grifols on 9 of the 15 factors compared between the two stocks.
Get Context Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Context Therapeutics Competitors List
Related Companies and Tools
